Overview
A Johns Hopkins study investigating whether tirzepatide (a GLP-1 medication) can help manage binge-eating disorder and obesity. Involves a weekly injection, daily capsule, 11 guided-therapy sessions, and 16 visits over a year.
Eligibility
Adults 18+; BMI 30 or higher; recurrent binge-eating episodes
InclusionAdults 18+; BMI 30 or higher; recurrent binge-eating episodes
Location
Johns Hopkins, Baltimore, MD
Study Flyer
